• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email
    SC 13G/A 1 usna-13g_20231231.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* USANA HEALTH SCIENCES, INC. ---------------------------------------------------------------------------- (Name of Issuer) Common Stock ---------------------------------------------------------------------------- (Title of Class of Securities) 90328M107 ---------------------------------------------------------------------------- (CUSIP Number) December 29, 2023 ---------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [_] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 90328M107 13G Page 2 of 8 Pages ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only). Renaissance Technologies LLC 26-0385758 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 1,198,697 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 0 _____________________________ (7) SOLE DISPOSITIVE POWER 1,198,697 _____________________________ (8) SHARED DISPOSITIVE POWER 0 ______________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,198,697 ------------------------------------------------------------------------------ (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ------------------------------------------------------------------------------ (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.27 % ------------------------------------------------------------------------------ (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA Page 2 of 8 pages ============================================================================= Page 3 of 8 pages ----------------------------------------------------------------------------- CUSIP NO. 90328M107 13G Page 3 of 8 Pages ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). RENAISSANCE TECHNOLOGIES HOLDINGS CORPORATION 13-3127734 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 1,198,697 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 0 _____________________________ (7) SOLE DISPOSITIVE POWER 1,198,697 _____________________________ (8) SHARED DISPOSITIVE POWER 0 _____________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,198,697 ----------------------------------------------------------------------------- (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ----------------------------------------------------------------------------- (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.27 % ----------------------------------------------------------------------------- (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC Page 3 of 8 pages ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 90328M107 13G Page 4 of 8 Pages ----------------------------------------------------------------------------- Item 1. (a) Name of Issuer USANA HEALTH SCIENCES, INC. (b) Address of Issuer's Principal Executive Offices. 3838 West Parkway Blvd., Salt Lake City, Utah 84120 Item 2. (a) Name of Person Filing: This Schedule 13G is being filed by Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC"). (b) Address of Principal Business Office or, if none, Residence. The principal business address of the reporting persons is: 800 Third Avenue New York, New York 10022 (c) Citizenship. RTC is a Delaware limited liability company, and RTHC is a Delaware corporation. (d) Title of Class of Securities. Common Stock (e) CUSIP Number. 90328M107 Page 4 of 8 pages ============================================================================= Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13-d-2(b) or (c),check whether the person filing is a: (a) [_] Broker or dealer registered under section 15 of the Act. (b) [_] Bank as defined in section 3(a)(6) of the Act. (c) [_] Insurance Company as defined in section 3(a)(19) of the Act. (d) [_] Investment Company registered under section 8 of the Investment Company Act. (e) [x] Investment Adviser in accordance with Sec.240.13d-1(b)(1)(ii)(E). (f) [_] Employee Benefit Plan or Endowment Fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F). (g) [_] Parent holding company, in accordance with Sec.240.13d-1(b)(1)(ii)(G). (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) [_] Group, in accordance with Sec.240.13d-1(b)(1)(ii)(J). Item 4. Ownership. (a) Amount beneficially owned. RTC: 1,198,697 shares RTHC: 1,198,697 shares, comprising the shares beneficially owned by RTHC, because of RTHC's majority ownership of RTC. (b) Percent of Class. RTC: 6.27 % RTHC: 6.27 % (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: RTC: 1,198,697 RTHC: 1,198,697 (ii) Shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: RTC: 1,198,697 RTHC: 1,198,697 (iv) Shared power to dispose or to direct the disposition of: RTC: 0 RTHC: 0 Page 5 of 8 pages ============================================================================= Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [_] Item 6. Ownership of More than Five Percent on Behalf of Another Person. Certain funds and accounts managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable Item 8. Identification and Classification of Members of the Group. Not applicable Item 9. Notice of Dissolution of a Group. Not applicable Page 6 of 8 pages ============================================================================= Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 2024 Renaissance Technologies LLC By: /s/ Brian Felczak Chief Financial Officer Renaissance Technologies Holdings Corporation By: /s/ Brian Felczak Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001). Page 7 of 8 Pages ============================================================================== EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING UNDER RULE 13D-1(K) OF THE EXCHANGE ACT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the shares of Common Stock of USANA HEALTH SCIENCES, INC. Date: February 13, 2024 Renaissance Technologies LLC By: /s/ Brian Felczak Chief Financial Officer Renaissance Technologies Holdings Corporation By: /s/ Brian Felczak Vice President Page 8 of 8 Pages
    Get the next $USNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • USANA Releases 2024 Sustainability Report

      Highlighting USANA's ongoing commitment to people, planet, and products SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- As a global leader in health and wellness, USANA is dedicated to doing its part in creating a better, healthier world. And with a commitment to positive business practices, USANA recently released its fifth annual sustainability report. This review of USANA's 2024 sustainability efforts and progress includes organizational priorities based on a comprehensive stakeholder assessment. To view the full 2024 sustainability report, please click here. "In unveiling our

      5/8/25 8:56:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kevin Guest Shares Transformative Success Strategies on Executive Coaching Day, May 1

      SALT LAKE CITY, May 1, 2025 /PRNewswire/ -- Kevin Guest, Executive Chairman at USANA Health Sciences (NYSE:USNA) and acclaimed author of All the Right Reasons, 12 Timeless Principles for Living a Life in Harmony, is sharing valuable insights for professionals striving to reach their peak potential. As part of Executive Coaching Day on May 1, Guest is combining decades of leadership experience with principles outlined in his bestselling book to offer actionable steps for success both in the boardroom and in life. "True success isn't just about achieving your goals; it's about l

      5/1/25 7:47:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Celavive Postbiotic Rescue Serum Selected as a Good Housekeeping 2025 Beauty Award Winner

      SALT LAKE CITY, April 28, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, announced today that its Celavive Postbiotic Rescue Serum was named as a winner in Good Housekeeping's 2025 Beauty Awards. The full list of awards can be found here. To learn more about USANA and the science behind its products, please visit USANA.com. "We're so excited that our Postbiotic Rescue Serum has been named a Good Housekeeping 2025 Beauty Award winner," said Brent Neidig, USANA's chief commercial officer. "Our product and R&D teams have put so much time

      4/28/25 7:27:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Iiekking G Doug sold $134,662 worth of shares (4,548 units at $29.61), closing all direct ownership in the company (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/12/25 10:42:33 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Wood Timothy E converted options into 674 shares and covered exercise/tax liability with 169 shares, increasing direct ownership by 7% to 7,442 units (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/6/25 4:02:48 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Winssinger Frederic J converted options into 674 shares, increasing direct ownership by 13% to 5,871 units (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/6/25 4:01:06 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    See more
    • USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

      SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

      4/1/25 7:47:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Appoints New Chief Scientific Officer

      Dr. Kathryn Armstrong brings 17 years of scientific expertise to the company SALT LAKE CITY, Jan. 22, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024.  Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.

      1/22/25 7:07:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Executive Chairman Kevin Guest Encourages Connections with July's "Social Wellness Month"

      SALT LAKE CITY, July 1, 2024 /PRNewswire/ -- Throughout July, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is emphasizing boosting social connections during "Social Wellness Month." Social wellness—the ability to form meaningful relationships and interact positively with others—not only enhances our emotional well-being but also significantly impacts our overall health. "Strong social connections reduce stress, improve mental health, and even extend life expectancy," said Guest. "In a world where digital interactions often replace face-to-face communic

      7/1/24 7:13:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    SEC Filings

    See more
    • SEC Form 10-Q filed by USANA Health Sciences Inc.

      10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/6/25 2:42:26 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by USANA Health Sciences Inc.

      DEFA14A - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/1/25 4:44:16 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by USANA Health Sciences Inc.

      SCHEDULE 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      4/30/25 11:13:38 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sidoti initiated coverage on USANA

      Sidoti initiated coverage of USANA with a rating of Buy

      6/23/23 9:12:38 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA downgraded by Jefferies with a new price target

      Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

      7/7/22 9:35:48 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • DA Davidson initiated coverage on USANA with a new price target

      DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

      4/14/22 7:45:27 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/13/24 10:49:58 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/13/23 11:26:45 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/11/22 3:48:24 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Financials

    Live finance-specific insights

    See more
    • USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 million versus $228 million, representing year-over-year growth of 10% and 12% in constant currency. Net earnings of $9.4 million versus $16.5 million. Diluted EPS of $0.49 as compared with $0.86. Adjusted diluted EPS(1) of $0.73 as compared with $0.86. Adjusted EBITDA(2) of $30 million versus $33 million. Direct selling Active Customers of 459,000 versus 494,000. Hiya Active Monthly Subscribers of 224,000. Company reiterates fiscal year 2025 outlook. Q1 2025 Financia

      4/22/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Schedules First Quarter 2025 Earnings Release and Conference Call

      USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2025 results will be released after the close of market on Tuesday, April 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, April 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures hi

      4/8/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Health Sciences Reports Fourth Quarter and Full Year 2024 Results and Provides Fiscal Year 2025 Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) (the "Company") today announced financial results for its fiscal fourth quarter and fiscal year ended December 28, 2024. The Company completed the acquisition of a 78.8% controlling ownership stake of Hiya Health Products, LLC ("Hiya") on December 23, 2024. Consequently, the Company's fourth quarter and fiscal year 2024 include the effect of less than a week of Hiya's operating results, which were not significant to the Company's consolidated results for the same periods. In light of the Hiya acquisition, the Company is now including metrics for Adjusted diluted EPS(1) and Adjusted EBITDA(2). Net earnings, Diluted EPS, Adjusted diluted EPS(1) and Adju

      2/25/25 4:10:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care